0.515
price down icon6.35%   -0.0349
after-market Dopo l'orario di chiusura: .54 0.025 +4.85%
loading

Indaptus Therapeutics Inc Borsa (INDP) Ultime notizie

pulisher
Mar 26, 2025

Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register

Mar 26, 2025
pulisher
Mar 25, 2025

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times

Mar 25, 2025
pulisher
Mar 22, 2025

Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register

Mar 22, 2025
pulisher
Mar 21, 2025

Indaptus Therapeutics looks to raise $2.25M in private placement - MSN

Mar 21, 2025
pulisher
Mar 20, 2025

Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Indaptus reports progress in Decoy20 cancer therapy trial - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Indaptus tests new cancer therapy combination By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Indaptus tests new cancer therapy combination - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Groundbreaking Cancer Trial: Indaptus Combines Novel Decoy20 with Checkpoint Inhibitor - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Benzinga India

Mar 18, 2025
pulisher
Mar 18, 2025

Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Drop in Short Interest - Defense World

Mar 18, 2025
pulisher
Mar 13, 2025

INDAPTUS THERAPEUTICS Earnings Results: $INDP Reports Quarterly Earnings - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics reports full-year loss of $1.61 per share -March 13, 2025 at 07:40 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics Enrolls Over 20 Patients in Phase 1 Trial of Decoy20, Achieving Key Clinical Milestone - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

Registration Is Now Open For Tribe Public’s Webinar Event - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Registration Is Now Open For Tribe Public's Webinar Event 'Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Registration Is Now Open For Tribe Public’s Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - Nasdaq

Mar 12, 2025
pulisher
Mar 07, 2025

Indaptus Therapeutics extends patent portfolio in China, Japan, and Israel - BioSpectrum Asia

Mar 07, 2025
pulisher
Mar 05, 2025

Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Indaptus secures new patents in Asia and Israel for Decoy platform By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Indaptus secures new patents in Asia and Israel for Decoy platform - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Indaptus Therapeutics Secures New Patent Approvals in China, Japan, and Israel for Decoy Platform in HIV and HBV Treatment - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Can Indaptus' New Asian Patents Transform Its Position in the $4B Hepatitis B Market? - StockTitan

Mar 04, 2025
pulisher
Feb 25, 2025

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Indaptus Therapeutics (NASDAQ:INDP) Trading Down 0.6% – Should You Sell? - Defense World

Feb 25, 2025
pulisher
Feb 14, 2025

Indaptus Therapeutics Enters Standby Equity Purchase Deal With YA II PN -February 12, 2025 at 12:30 pm EST - Marketscreener.com

Feb 14, 2025
pulisher
Feb 12, 2025

Indaptus Therapeutics Enters Equity Purchase Agreement With Ya II Pn -February 12, 2025 at 09:29 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 06, 2025

Indaptus Therapeutics expands cancer trial to Canada - Investing.com India

Feb 06, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics Files Prospectus Relating To Proposed Resale By Selling Stockholders Of Up To 4.4 Million Shares - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics Expands Decoy20 Clinical Trial To Canada - Nasdaq

Feb 05, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics expands cancer trial to Canada By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - The Manila Times

Feb 05, 2025
pulisher
Feb 05, 2025

Major Clinical Trial Expansion: Indaptus' Cancer Immunotherapy Decoy20 Gets Canadian Green Light - StockTitan

Feb 05, 2025
pulisher
Feb 03, 2025

Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

Indaptus Therapeutics Receives Notification from Nasdaq Regarding Minimum Bid Price RequirementUnited States Securities and Exchange Commission, Washington, DC 20549Form 8-KIndaptus Therapeutics, Inc. recently received a notification from Nasda - Defense World

Feb 01, 2025
pulisher
Jan 15, 2025

Indaptus Therapeutics Announces $2.25 Million Private Placement - Defense World

Jan 15, 2025
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Capitalizzazione:     |  Volume (24 ore):